EASYRA ALBUMIN, CALCIUM, MAGNESIUM AND INORGANIC PHOSPHOROUS REAGENT

K101088 · Medica Corp. · CIX · Apr 4, 2011 · Clinical Chemistry

Device Facts

• Record ID: K101088
• Device Name: EASYRA ALBUMIN, CALCIUM, MAGNESIUM AND INORGANIC PHOSPHOROUS REAGENT
• Applicant: Medica Corp.
• Product Code: CIX · Clinical Chemistry
• Decision Date: Apr 4, 2011
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.1035
• Device Class: Class 2

Indications for Use

The EasyRA albumin reagent is intended for the quantitative determination of Albumin (ALB) in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Albumin measurements are used in the diagnosis and treatment of numerous diseases involving primarily the liver or kidneys. For in vitro diagnostic use only. The EasyRA total calcium reagent is intended for the quantitative measurement of Total Calcium (Ca) in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety if bone diseases, chronic renal disease and tetany. For in vitro diagnostic use only. The EasyRA magnesium reagent is intended for the quantitative measurement of Magnesium (Mg) in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Magnesium measurements are used in the diagnosis and treatment of: Hypermagnesemia occuring during renal failure, acute diabetic acidosis, dehydration or in Addison's disease. Hypomagnesemia observed in cases of chronic alcoholism, malabsorption, acute pancreatitis and kidney disorders. This reagent is intended for the quantitative measurement of Inorganic Phosphorous (PHOS) in human serum and plasma. Phosphorus measurements are used in the diagnosis and treatment of parathyroid gland, kidney diseases, and vitamin D imbalance.

Device Story

Ready-to-use liquid reagents for EasyRA clinical chemistry analyzer; measure albumin, calcium, magnesium, and inorganic phosphorus in human serum and plasma. Albumin uses bromocresol green binding (600/700 nm); Calcium uses Arsenazo III (650 nm) with 8-hydroxyquinoline-5-sulfonic acid to eliminate magnesium interference; Magnesium uses xylidyl blue-1 (520 nm); Phosphorus uses ammonium molybdate (340 nm). Analyzer performs quantitative colorimetric/AZO dye analysis; results displayed to clinicians for diagnostic decision-making regarding liver, kidney, and metabolic health. Intended for clinical laboratory use.

Clinical Evidence

No clinical data provided; substantial equivalence is based on bench testing and performance characteristics of the reagents on the EasyRA Chemistry Analyzer.

Technological Characteristics

Liquid ready-to-use reagents. Colorimetric/AZO dye sensing principles. Analyzers: MEDICA EasyRA. Connectivity: Standalone clinical chemistry analyzer. Software: Embedded firmware for automated photometric measurement and calculation. Standards: CLSI EP5-A2 (precision), CLSI EP9-A2 (method comparison).

Indications for Use

Indicated for quantitative measurement of albumin, calcium, magnesium, and inorganic phosphorus in human serum and plasma for clinical laboratory diagnosis and treatment of liver, kidney, parathyroid, and bone diseases, as well as metabolic disorders like tetany, acidosis, and dehydration.

Regulatory Classification

Identification

An albumin test system is a device intended to measure the albumin concentration in serum and plasma. Albumin measurements are used in the diagnosis and treatment of numerous diseases involving primarily the liver or kidneys.

Submission Summary (Full Text)

{0}

1

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE

A. 510(k) Number:
k101088

B. Purpose for Submission:
Albumin: Addition of plasma to the already cleared device (k080874)
Calcium: Addition of plasma to the already cleared device (k072249)
Magnesium: Addition of plasma to the already cleared device (k092737)
Phosphorus: Addition of plasma to the already cleared device (k080810)

C. Measurand:
Albumin, Calcium, Magnesium, Phosphorus

D. Type of Test:
Albumin, Magnesium, Phosphorus: Quantitative colorimetric chemistry tests
Calcium: AZO method

E. Applicant:
Medica Corp

F. Proprietary and Established Names:
EasyRA ALB Reagent
Easy RA Calcium Reagent
Easy RA Magnesium Reagent
Easy RA Inorganic Phosphorus Reagent

G. Regulatory Information:

{1}

| Measurand | Regulation Section | Classification | Product Code | Panel |
| --- | --- | --- | --- | --- |
| Albumin | 21CFR862.1035 | 2 | CIX-Colorimetric | Clinical Chemistry |
| Calcium | 21CFR862.1145 | 2 | CJY–Azo Dye | Clinical Chemistry |
| Magnesium | 21CFR862.1495 | 2 | JGJ-Photometric | Clinical Chemistry |
| Phosphorus-Inorganic | 21CFR862.1580 | 2 | CEO – Colorimetric | Clinical Chemistry |

# H. Intended Use:

1. Intended use(s):

See Indications for use below.

2. Indication(s) for use:

EasyRA Albumin Reagent: The EasyRA albumin reagent is intended for the quantitative determination of albumin (ALB) in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Albumin measurements are used in the diagnosis and treatment of numerous diseases involving primarily the liver or kidneys. For in vitro diagnostic use only.

EasyRA Calcium Reagent: The EasyRA total calcium reagent is intended for the quantitative measurement of total calcium (Ca) in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety if bone diseases, chronic renal disease and tetany. For in vitro diagnostic use only.

EasyRA Magnesium Reagent: The EasyRA magnesium reagent is intended for the quantitative measurement of magnesium in human serum and plasma, using the MEDICA "EasyRA Chemistry Analyzer" in clinical laboratories. Magnesium measurements are used in the diagnosis and treatment of: Hypermagnesemia occurring during renal failure, acute diabetic acidosis, dehydration or in Addison's disease. Hypomagnesemia observed in cases of chronic alcoholism, malabsorption, acute pancreatitis and kidney disorders.

EasyRA Inorganic Phosphorus Reagent: This reagent is intended for the quantitative measurement of inorganic phosphours (PHOS) in human serum and

{2}

plasma. Phosphorus measurements are used in the diagnosis and treatment of parathyroid gland, kidney diseases, and vitamin D imbalance.

3. Special conditions for use statement(s):

Prescription use

4. Special instrument requirements:

EasyRA Clinical Chemistry Analyzer

I. Device Description:

The EasyRA albumin (ALB), calcium (Ca), magnesium (Mg), and inorganic phosphorus reagents are in vitro diagnostic reagents in ready-for use liquid form. They are designed for use on the Easy RA clinical chemistry analyzer for the measurement of their respective analytes in human serum and plasma.

J. Substantial Equivalence Information:

1. Predicate Device Name(s):

EasyRA Albumin Reagent

EasyRA Calcium Reagent

EasyRA Magnesium Reagent

EasyRA Phosphorus Inorganic Reagent

2. Predicate 510(k) number(s):

k080874, k080810, k072249, k092737

3. Comparison with predicate:

| Similarities and Differences for Albumin | | |
| --- | --- | --- |
| Item | Candidate Device
EasyRA Albumin Reagent | Predicate Device
(k080874)
EasyRA Albumin
Reagent |
| Intended Use | The EasyRA albumin reagent is intended for the quantitative determination of albumin (ALB) in human serum and plasma, using the MEDICA “EasyRA Chemistry Analyzer” in clinical laboratories. Albumin measurements are used in the diagnosis and treatment of numerous diseases involving primarily the liver or kidneys. For in vitro diagnostic use only. | Same |

{3}

| Similarities and Differences for Calcium | | |
| --- | --- | --- |
| Item | Candidate Device
EasyRA Calcium Reagent | Predicate Device
(k072249)
EasyRA Calcium Reagent |
| Intended Use | The EasyRA total calcium reagent is intended for the quantitative measurement of total calcium (Ca) in human serum and plasma, using the MEDICA “EasyRA Chemistry Analyzer” in clinical laboratories. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety if bone diseases, chronic renal disease and tetany. For in vitro diagnostic use only. | Same |
| Specimen Type | Serum and plasma | Serum |
| Reagent Type | Liquid ready-for-use | Same |
| Assay Principle | AZO dye | Same |
| Analytical Range | 1.0 to 15 mg/dL | Same |
| Similarities and Differences for Magnesium | | |
| --- | --- | --- |
| Item | Candidate Device
EasyRA Magnesium Reagent | Predicate Device
(k092737)
EasyRA
Magnesium
Reagent |
| Intended Use | The EasyRA total calcium reagent is intended for the quantitative measurement of total calcium (Ca) in human serum and plasma, using the MEDICA “EasyRA Chemistry Analyzer” in clinical laboratories. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety if bone diseases, chronic renal disease and | Same |

{4}

5

| Similarities and Differences for Phosphorus-Inorganic | | |
| --- | --- | --- |
| Item | Candidate Device
EasyRA Inorganic Phosphorus Reagent | Predicate Device
(k092737)
EasyRA
Phosphorus
Inorganic Reagent |
| Intended Use | The EasyRA total calcium reagent is intended for the quantitative measurement of total calcium (Ca) in human serum and plasma, using the MEDICA “EasyRA Chemistry Analyzer” in clinical laboratories. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety if bone diseases, chronic renal disease and tetany. For in vitro diagnostic use only. | Same |
| Specimen Type | Serum and plasma | Serum |
| Reagent Type | Liquid ready-for-use | Same |
| Assay Principle | Colorimetric | Same |
| Analytical Range | 0.11 to 20.0 mg/dL | Same |

K. Standard/Guidance Document Referenced (if applicable):

- CLSI Guideline, EP5-A2 Evaluation of Precision Performance of Clinical Chemistry Devices – Second Edition
- CLSI Guideline, EP9-A2 Method Comparison and Bias Estimation Using Patient Samples – Second Edition

L. Test Principle:

Easy RA Albumin

This method involves the binding of albumin with bromocresol green to produce a

{5}

blue-green color. This color is measured at 600 nm with a blanking wavelength of 700 nm. The color intensity is proportional to the concentration of Albumin in the sample.

## EasyRA Calcium

This method utilizes Arsenazo III, which has a high affinity for calcium at neutral pH. Interference from magnesium is eliminated by the addition of 8-hydroxyquinoline-5-sulfonic acid. Arsenazo III reacts with calcium to form a 1:1 blue complex with an absorption maximum at 650 nm. The concentration of calcium is proportional to the intensity of the blue color.

## EasyRA Magnesium

This method involves the binding of xylidyl blue-1 dye to magnesium to form the Mg-xylidyl blue complex. The increase of absorbance of the complex at 520 nm is directly proportional to the concentration of magnesium in the sample.

The absorbance decrease at 600 nm is directly proportional to the Magnesium in the serum combining with the complex.

## EasyRA Phosphorus-Inorganic

This method involves the reaction of inorganic phosphorus with ammonium molybdate in an acidic medium to form a phosphomolybdate complex with a yellow color.

The increase in absorbance at 340 nm is directly proportional to the concentration of inorganic phosphorus in the sample.

## M. Performance Characteristics (if/when applicable):

### 1. Analytical performance:

#### a. Precision/Reproducibility:

**Serum and Plasma**- Precision studies were performed in conjunction with the matrix comparison study with lithium heparin tubes. Duplicate plasma and serum samples from the method studies were calculated for average SD for 3 partitioned bins covering the ranges tested. The average SD in each of the 3 bins for both plasma and serum are comparable.

Albumin

| | Low | Medium | High |
| --- | --- | --- | --- |
| Analytical Range(g/dL) | 0.4 – 4.75 | 4.75 – 4.99 | 5.0 – 7.0 |

{6}

| No. of Samples | 24 | 25 | 22 |
| --- | --- | --- | --- |
| No. of Replicates | 2 | 2 | 2 |
| | | | |
| Serum Mean | 3.72 | 4.86 | 5.25 |
| Serum SD | 0.060 | 0.051 | 0.056 |
| Serum % CV | 1.60 | 1.00 | 1.10 |
| | | | |
| Plasma Mean | 3.57 | 4.87 | 5.27 |
| Plasma SD | 0.050 | 0.062 | 0.054 |
| Plasma % CV | 1.40 | 1.30 | 1.00 |

Calcium

| | Low | Medium | High |
| --- | --- | --- | --- |
| Analytical Range(mg/dL) | 1.0 – 9.5 | 9.5 – 10.0 | 10.0 – 15.0 |
| No. of Samples | 19 | 31 | 20 |
| No. of Replicates | 2 | 2 | 2 |
| | | | |
| Serum Mean | 7.89 | 9.79 | 10.80 |
| Serum SD | 0.15 | 0.14 | 0.14 |
| Serum % CV | 1.90 | 1.40 | 1.30 |
| | | | |
| Plasma Mean | 7.78 | 9.58 | 10.60 |
| Plasma SD | 0.11 | 0.15 | 0.15 |
| Plasma % CV | 1.40 | 1.60 | 1.40 |

Magnesium

| | Low | Medium | High |
| --- | --- | --- | --- |
| Analytical Range(mg/dL) | 0.03 – 1.8 | 1.8 – 1.95 | 1.95 – 6.1 |
| No. of Samples | 16 | 27 | 29 |
| No. of Replicates | 2 | 2 | 2 |
| | | | |
| Serum Mean | 1.45 | 1.88 | 2.81 |
| Serum SD | 0.023 | 0.020 | 0.036 |
| Serum % CV | 1.60 | 1.10 | 1.30 |
| | | | |
| Plasma Mean | 1.42 | 1.86 | 2.80 |
| Plasma SD | 0.020 | 0.026 | 0.041 |
| Plasma % CV | 1.40 | 1.40 | 1.50 |

{7}

Phosphorus

| | Low | Medium | High |
| --- | --- | --- | --- |
| Analytical Range(mg/dL) | 0.11 – 3.25 | 3.25 – 3.75 | 3.75 – 20.0 |
| No. of Samples | 22 | 29 | 26 |
| No. of Replicates | 2 | 2 | 2 |
| | | | |
| Serum Mean | 2.67 | 3.52 | 8.19 |
| Serum SD | 0.041 | 0.049 | 0.078 |
| Serum % CV | 1.50 | 1.40 | 1.00 |
| | | | |
| Plasma Mean | 2.46 | 3.26 | 8.04 |
| Plasma SD | 0.044 | 0.046 | 0.094 |
| Plasma % CV | 1.80 | 1.40 | 1.20 |

In addition a simplified within-run precision study was performed on the EasyRA analyzer by analyzing 3 plasma patient samples, 20 consecutive times. The within-run precision data is summarized in the table below:

| | Mean | SD | %CV |
| --- | --- | --- | --- |
| Albumin (g/dL) | Level 1 - 3.21 | Level 1 - 0.03 | Level 1 - 0.96 |
| | Level 2 - 4.82 | Level 2 - 0.09 | Level 2 - 1.82 |
| | Level 3 - 6.38 | Level 3 - 0.06 | Level 3 - 0.86 |
| Calcium (mg/dL) | Level 1 - 5.68 | Level 1 - 0.09 | Level 1 - 1.56 |
| | Level 2 - 10.66 | Level 2 - 0.13 | Level 2 - 1.26 |
| | Level 3 - 11.82 | Level 3 - 0.10 | Level 3 - 0.88 |
| Magnesium (mg/dL) | Level 1 - 1.21 | Level 1 - 0.01 | Level 1 - 0.99 |
| | Level 2 - 2.02 | Level 2 - 0.03 | Level 2 - 1.68 |
| | Level 3 - 4.92 | Level 3 - 0.07 | Level 3 - 1.40 |
| Phosphorus (mg/dL) | Level 1 - 2.11 | Level 1 - 0.02 | Level 1 - 0.98 |
| | Level 2 - 3.26 | Level 2 - 0.04 | Level 2 - 1.22 |
| | Level 3 - 15.06 | Level 3 - 0.12 | Level 3 - 0.77 |

# b. Linearity/assay reportable range:

Plasma - Linearity studies were not conducted in plasma. See previously cleared linearity data in k080810 (ALB), k072249 (Ca), k092737 (Mg), and k080810 (PHOS) for serum samples. The linear reportable ranges for each assay are summarized below.

| | Albumin | Calcium | Magnesium | Phosphorus |
| --- | --- | --- | --- | --- |
| Linear Reportable Range | 0.4 to 7.0 g/dL | 1.0 to 15.0 mg/dL | 0.04 to 6.1 mg/dL | 0.11 to 20.0 mg/dL |

{8}

An extended linearity study was performed for all analytes with the MEDICA EasyRA analyzer to evaluate accuracy and precision. The sponsor recommends a dilution of 1:2 when the patient albumin, calcium, magnesium, and phosphorus results in plasma fall outside the upper measuring range of 7.0 g/dL, 15.0 mg/dL, 6.1 mg/dL, and 20.0 mg/dL, respectively. A dilution study was performed for albumin on 3 different patient plasma samples spiked with standard albumin stock solution to increase the albumin level in the range of 7.5 to 13.5 g/dL, for calcium 5 different patient plasma samples were spiked with standard calcium stock solution to increase the calcium level in the range of 17.0 to 27.0 mg/dL, for magnesium 5 different patient plasma samples were spiked with standard magnesium stock solution to increase the magnesium level in the range of 6.5 to 11.7 mg/dL, and for phosphorus 5 different patient plasma samples were spiked with standard phosphorus stock solution to increase the phosphorus level in the range of 22.0 to 37.0 mg/dL. Each sample was then diluted with saline at 1:2 dilution by the analyzer or manually. Each diluted sample was run in triplicate on two MEDICA EasyRA analyzers. The % recovery range of the system for each analyte is provided in the table below:

| | EasyRA % Recovery |
| --- | --- |
| Albumin | 101.1 to 102.6 |
| Calcium | 99.3. to 102.6 |
| Magnesium | 100.7 to 104.0 |
| Phosphorus | 96.8 to 104.5 |

In addition a simplified within-run precision study was performed in the extended linearity range for all analytes by analyzing 3 plasma samples, 20 consecutive times. The within-run precision data is summarized in the table below:

| | Mean | SD | CV |
| --- | --- | --- | --- |
| Albumin | Level 1 - 7.73 | Level 1 - 0.08 | Level 1 - 1.04 |
| | Level 2 - 9.75 | Level 2 - 0.18 | Level 2 - 1.84 |
| | Level 3 - 12.69 | Level 3 - 0.23 | Level 3 - 1.78 |
| Calcium | Level 1 - 18.73 | Level 1 - 0.18 | Level 1 - 0.95 |
| | Level 2 - 24.65 | Level 2 - 0.25 | Level 2 - 1.00 |
| | Level 3 - 26.64 | Level 3 - 0.32 | Level 3 - 1.20 |
| Magnesium | Level 1 - 6.77 | Level 1 - 0.08 | Level 1 - 1.15 |
| | Level 2 - 8.20 | Level 2 - 0.11 | Level 2 - 1.29 |
| | Level 3 - 9.90 | Level 3 - 0.13 | Level 3 - 1.34 |
| Phosphorus | Level 1 - 26.14 | Level 1 - 0.30 | Level 1 - 1.14 |

{9}

10

| | Level 2 – 30.35
Level 3 – 33.66 | Level 2 – 0.19
Level 3 – 0.47 | Level 2 – 0.62
Level 3 – 1.39 |
| --- | --- | --- | --- |

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Calibrators were previously cleared under k080810 (ALB), k072249 (Ca), k092737 (Mg), and k080810 (PHOS).

d. Detection limit:

Limit of detection studies were not conducted for plasma. See cleared serum data under k080810 (Albumin), k072249 (Calcium), k092737 (Magnesium), and k080810 (Phosphorus).

e. Analytical specificity:

Plasma interference studies were not performed. See previously cleared interference data in k080810 (Albumin), k072249 (Calcium), k092737 (Magnesium), and k080810 (Phosphorus) for serum samples.

f. Assay cut-off:

Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

Plasma – See previously cleared method comparison data in k080810 (Albumin), k072249 (Calcium), k092737 (Magnesium), and k080810 (Phosphorus) for serum samples. Plasma matrix comparison data is provided below in part (b) of this section.

b. Matrix comparison:

Plasma Lithium Heparin- A matrix comparison study was also performed in conjunction with CLSI EP9-A2 guidelines using lithium heparin tubes. The study was completed with human plasma and serum samples spanning the linear range of each assay. 71 total samples (60 unaltered and 11 altered samples) were analyzed for albumin, 70 total samples (56 unaltered and 14 altered samples) were analyzed for calcium, 72 total samples (59 unaltered and 13 altered) were analyzed for magnesium, and 77 total samples (61 unaltered and 16 altered samples) were analyzed for phosphorus. Each sample was analyzed in duplicate using the MEDICA EasyRA chemistry analyzer.

{10}

One single set of plasma samples were used as test samples, while duplicate serum samples were used as references. Determined linear regression correlations are as follows:

| Analyte | Slope | Intercept | R2 | Conc. Range Tested |
| --- | --- | --- | --- | --- |
| ALB | 1.0056 | -0.0192 | 0.9937 | 0.4 – 6.6 g/dL |
| Ca | 0.9853 | -0.0632 | 0.9891 | 1.6 – 14.7 mg/dL |
| Mg | 1.0184 | -0.0584 | 0.9983 | 0.1 – 6.1 mg/dL |
| PHOS | 1.0070 | -0.2462 | 0.9966 | 0.7 – 19.3 mg/dL |

# 3. Clinical studies:

a. Clinical Sensitivity:

Not applicable.

b. Clinical specificity:

Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable.

# 4. Clinical cut-off:

Not applicable.

# 5. Expected values/Reference range:

Reference ranges are provided in the labeling from literature as follows:

| | Serum/Plasma |
| --- | --- |
| Albumin | 3.8 – 5.1 g/dL |
| Calcium | 8.8 – 10.2 mg/dL |
| Magnesium | 1.6 – 2.6 mg/dL |
| Phosphorus | 2.7 – 4.5 mg/dL |

Tietz, N.W. Fundamentals of Clinical Chemistry, $5^{\text{th}}$ ed., Philadelphia, PA, WB Saunders and Co., p. 961-1027; 2001.

{11}

N. Proposed Labeling:

The labeling is sufficient and does satisfy the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

12